Lv3
202 积分 2024-11-20 加入
Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial
5个月前
已完结
Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis
5个月前
已完结
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial
5个月前
已完结
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
5个月前
已完结
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
5个月前
已完结
Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist
5个月前
已完结
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?
5个月前
已完结
Recent advances in therapeutic cancer vaccines
6个月前
已完结
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
6个月前
已完结
皖公网安备34019202002308
